Evaluating and Supporting Patients Presenting With Fatigue Following COVID-19
“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention. ”
The fully captioned video and edited transcript will be posted within the next few days.
This COCA Call will be held on Friday, March 27, 2020
During this COCA Call, presenters will discuss Post-COVID conditions (PCC), an umbrella term for the wide range of health consequences present four or more weeks after infection with SARS-CoV-2, which includes Long-COVID. It can be difficult to distinguish symptoms of fatigue and post-exertional malaise caused by PCC from symptoms that occur for other reasons. The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has recently published a Multi-Disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Fatigue in PCC. It provides practical guidance to clinicians when assessing and treating individuals with fatigue and a history consistent with PCC. The burden of PCC is expected to reflect the disproportionate burden of infection by race, ethnicity, and socioeconomic status and to highlight ongoing inequities in healthcare. The Health Equity Work Group of the AAPM&R has developed guidance to highlight the central role that principles of diversity, equity, and inclusion play in delivering quality healthcare.
Maureen Miller, MD, MPH
Research, Surveillance, and Management Unit
Natural History/Post-COVID Conditions Team
Epidemiology Task Force
Centers for Disease Control and Prevention
Joseph E. Herrera, DO
Professor and System Chair of Rehabilitative Medicine
Department of Rehabilitation and Physical Medicine
Mount Sinai Health System
Monica Verduzco Gutierrez, MD
Professor and Chair of Physical Medicine and Rehabilitation
Department of Physical Medicine and Rehabilitation
UT Health San Antonio
Benjamin Abramoff, MD, MS
Assistant Professor of Clinical Physical Medicine and Rehabilitation
Department of Physical Medicine and Rehabilitation
None at this time
Thursday, September 30, 2021,
2:00 PM – 3:00 PM ET
US: +1 669 254 5252
or +1 646 828 7666
or +1 551 285 1373
or +1 669 216 1590
US: +16692545252,,1603742224#,,,,*907646# or +16468287666,,1603742224#,,,,*907646#
Webinar ID: 160 374 2224Add to Calendar
Registration is not required.
Date: Thursday, September 30, 2021
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar begins, please click the link below to join:
Webinar ID: 160 374 2224
Dial-in US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
One-tap mobile: US: +16692545252,,1603742224#,,,,*907646# or +16468287666,,1603742224#,,,,*907646#
International numbers available: https://www.zoomgov.com/u/abr5yI4gWOexternal icon
- Determine which clinical assessments and tests are needed for an individual patient with fatigue.
- Explain how post-exertional malaise impacts patient management.
- Describe how to apply health equity considerations to clinical care, activity management, and reconditioning of long COVID patients.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
- American Academy of Physical Medicine and Rehabilitation (AAPM&R)’s Long COVID Resource Webpageexternal icon
- AAPM&R Multi-Disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Fatigue in Post-Acute Sequelae of SARS-CoV-2 (PASC) Patientsexternal icon
- AAPM&R PASC Guidance Statement Methodology Publicationexternal icon
- World Health Organization: Expanding Our Understanding of Post COVID-19 Condition: Webinar 2external icon
- CDC’s Interim Guidance for Evaluating and Caring for Patients with Post-COVID Conditions
- CDC Resources on Long COVID:
To receive continuing education (CE) for WC2922-093021 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Patients Presenting With Fatigue Following COVID-19, Thursday, September 30, 2021, please visit TCEO and follow these 9 Simple Steps by Monday, November 1, 2021.
To receive continuing education (CE) for WD2922-093021 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Patients Presenting With Fatigue Following COVID-19, Thursday, June 3, 2021, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, November 2, 2021, and Thursday, November 2, 2023.
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-21-232-L04-P and enduring JA4008229-0000-21-233-H04-P course category.
This program has been designated knowledge based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1.0 CPH recertification credits for this program.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at firstname.lastname@example.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters, except Benjamin Abramoff would like to disclose that he does receive honorarium for educational grand rounds when he presents on post-acute sequelae of SARS-CoV-2 infection (PASC) that are arranged through Medical Education Speakers Network.
Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use, except part of the presentation will address the use of COVID-19 vaccine outside of approved age group, except parts of the presentation will discuss treatments for COVID and long COVID which are all under investigational use.
CDC did not accept commercial support for this continuing education activity.
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.